


Digilab 30R Pneuma-Tonometer



Digilab's Model 30R Pneuma-Tonometer's unique gentle sensor allows sufficient contact time with the eyes to provide objective steady state measurement values not subject to the variabilities inherent with instantaneous reading and subjective measuring tonometers. The easy-to-use sensor also minimizes the effect of patient apprehension and operator error.

It is also a unique diagnostic aid because it graphically depicts and measures the symmetry or absence of symmetry of ocular pulse and I.O.P. of the two eyes and the alterations resulting from a change of body position.

Differences between eyes in ocular pulse amplitude and I.O.P. can be an indication of vascular and ocular disorders. Asymmetries in intraocular pressures and in the form and amplitudes of intraocular pulse were not found in normal subjects.

Keeler Instruments Limited
21-27 Marylebone Lane London W1M 6DS
Telephone: 01-935 8512



Dosage and Administration

Adult: One drop to be instilled into the eye once or twice daily or at the discretion of the physician. Children: At the discretion of the physician.

Contra-Indications, Warnings, etc.

GANDA should not be used in the case of a narrow angle between the iris and cornea as pupillary dilation may precipitate angle closure.

Occasionally a patient may complain of orbital discomfort or red eye (hyperaemia).

Rarely, headache, irritation and local skin reactions may occur. As with other adrenaline preparations, melanosis may occasionally occur, but this has no pathological significance.

Systemic effects are rare but include tachycardia, extrasystoles, and elevation of blood pressure.

One clinical investigator has reported that in two cases out of 21, a paradoxical increase in I.O.P. occurred for which no explanation was offered.

Some degree of ptosis may represent an adverse effect in glaucoma, but will usually respond to a reduction in dosage or in the frequency of administration.

At prolonged high dosage a tendency to superficial punctate keratitis has been reported, responding either to a reduction in dosage or interruption of treatment.

When used in conjunction with miotics, GANDA should follow the miotic after an interval of 5-10 minutes.

Pharmaceutical Precautions

GANDA is supplied in a plastic dropper bottle in a nitrogen-filled pouch, inside a carton. It should be stored in its carton in a cool place away from strong light. The carton only should be removed before supplying to the patient. GANDA should not be diluted, nor should it be dispensed from any container other than the original bottle. GANDA should not be used if the solution has become dark amber. The contents of the bottle should be discarded one month after removal from the pouch. GANDA is fully potent for two years providing the pouch remains unopened.

Product Licence Numbers

GANDA 3 + 0.5 0033/0071
GANDA 5 + 0.5 0033/0070
GANDA 5 + 1 0033/0069

30.5

50.5 | 5 1

GANDA®

Guanethidine monosulfate B.P.

3%	5%	5%
----	----	----

 w/v
Adrenaline B.P.

0.5%	0.5%	1%
------	------	----

 w/v

**THE EFFECTIVE
NON-MIOTIC THERAPY FOR
OPEN ANGLE GLAUCOMA**

As a combination of guanethidine monosulfate and adrenaline in a single bottle, Ganda constitutes a complete therapy.

The potentiation of adrenaline by guanethidine forms the rational basis for this combination. The three formulations offer the clinician flexibility in treatment, and the twice daily dosage contributes to patient acceptability.



SMITH & NEPHEW PHARMACEUTICALS LTD.,
P.O. Box 7, Bessemer Road, Welwyn Garden City, Hertfordshire.